3 recruiting, 3 unknown, 1 completed. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Unknown 3, Completed 1 |
| Phase 2 | 3 | Recruiting 2, Unknown 1 |
Follow 68Ga-DOTATATE: new trials by email Literature Review of 68Ga-DOTATATE trials Research Report on 68Ga-DOTATATE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography - Recurrent Meningioma | Phase 1 / Phase 2 | Recruiting | Joshua Palmer | 30 | 2025-11-12 | 2026-08-13 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma 68Ga-MGS5 - Medullary Thyroid Carcinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 20 | 2023-06-21 | 2024-07-25 |
| Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors Al18F-NOTA-LM3, 68Ga-DOTATATE, 68Ga-NODAGA-LM3 - Neuroendocrine Tumors | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 80 | 2023-03-23 | 2025-04-02 |
| Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO 68Ga-Dotatate, 68Ga-DOTA-JR11 - Tumor-Induced Osteomalacia | Phase 1 | Unknown | Peking Union Medical College Hospital | 50 | 2020-03-15 | 2021-01-05 |
| Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas Computed Tomography, Gallium Ga 68-DOTATATE, Positron Emission Tomography - Meningioma | Phase 1 | Completed | M.D. Anderson Cancer Center | 13 | 2019-01-10 | 2023-09-01 |
Meningioma (2) · Paraganglioma (2) · Pheochromocytoma (2) · Carcinoma, Medullary (1) · Esthesioneuroblastoma, Olfactory (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Neuroendocrine Tumors (1) · Oncogenic osteomalacia (1)
National Cancer Institute (NCI) (2) · Peking Union Medical College Hospital (2) · First Affiliated Hospital of Fujian Medical University (1) · Joshua Palmer (1) · M.D. Anderson Cancer Center (1)
United States (4) · China (3)
Frank I Lin, M.D. (2) · Hongli Jing, MD (1) · Jason M Johnson (1) · Joshua D Palmer, MD (1) · Meixi Liu, MD (1) · Weibing Miao (1)